Overview

Efficacy and Safety of Inotuzumab Ozogamicin in Treating Adult Patients With Ph Negative ALL With Minimal Residual Disease Positive After Induction Chemotherapy

Status:
Not yet recruiting

Trial end date:
2025-06-30

Target enrollment:

Participant gender:

Summary

A single-center, single-arm, open-label, interventional, phase II clinical trial to evaluate the efficacy and safety of InO in B-ALL achieved CR/CRi after 1L induction chemotherapy with positive minimal residual disease.

Phase:

Phase 2

Details

Lead Sponsor:

Institute of Hematology & Blood Diseases Hospital

Treatments:

Inotuzumab Ozogamicin